



Check for updates

ORIGINAL ARTICLE

Psychological care program for participants of cancer genetic counseling with high risk of breast and ovarian cancer

Reyna J. Martínez-Arriaga¹, Leivy P. González-Ramírez¹, Azucena Del Toro-Valero², Rebeca Robles-García³, Antonio Oceguera-Villanueva², Livia Zagame², Aída A. Silva-García⁴ and Adrián Daneri-Navarro^{5*}

¹Health Sciences Division, Centro Universitario de Tonala, Universidad de Guadalajara, Tonala, Jal.; ²Genetics Service, Instituto Jalisciense de Cancerología, Guadalajara, Jal.; ³Epidemiological and Psychosocial Research Directorate, Instituto Nacional de Psiquiatría "Ramón de la Fuente Muñiz", Mexico City; ⁴Oncology Service, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, Jal.; ⁵Physiology Department, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jal. Mexico

Abstract

This paper describes the creation and implementation of a Psychological Care Program (PCP) that treats patients who assist at cancer genetic counseling. It was created due to a series of collaborations between Universidad de Guadalajara and various national and international health institutions. Program goals include to assess the psychological state, emotional and decision-making support, as well as the promotion of healthy lifestyles in participants of PCP. A psychological treatment was created based on psycho-oncology, health psychology, and cognitive behavioral and transtheoretical model. Multidisciplinary interaction has been an essential element for its implementation.

Key words: Psycho-oncology. Cancer genetic counseling. Breast cancer. Mental health. Psychosocial factors.

Programa de atención psicológica para participantes de asesoramiento genético oncológico con alto riesgo de cáncer de mama y ovario

Resumen

Este artículo describe la creación e implementación de un Programa de Atención Psicológica (PAP) que trata pacientes que asisten al servicio de Asesoramiento Genético Oncológico (AGO). Fue creado debido a una serie de colaboraciones entre la Universidad de Guadalajara y varios institutos de salud nacionales e internacionales. El objetivo del programa incluye evaluar el estado psicológico, brindar ayuda emocional y en la toma de decisiones, así como la promoción de estilos de vida saludables en los participantes del PCP. Se creó un tratamiento psicológico basado en la psicooncología, la psicología de la salud, el modelo cognitivo conductual y el modelo transteórico. Las interacciones multidisciplinarias han sido un elemento esencial para su implementación.

Palabras clave: Psicooncología. Asesoramiento genético oncológico. Cáncer de mama. Salud mental. Factores psicosociales.

Introduction

Mutations in BRCA1/BRCA2 genes and other non-BRCA1/2 genes cause about 5-15% of breast cancer

(BC) and ovarian cancer (OC)^{1,2}. Molecular studies to determine if mutations exist in these genes must be accompanied by a cancer genetic counseling (CGC). The CGC which helps participants to understand and

Correspondence:

*Adrián Daneri-Navarro

E-mail: daneri@cuucs.udg.mx

2565-005X/© 2020 Sociedad Mexicana de Oncología. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Date of reception: 07-11-2019

Date of acceptance: 15-04-2020

DOI: 10.24875/j.gamo.20000372

Available online: 02-06-2020

Gac Mex Oncol. 2020;19(4):143-151

www.gamo-smeo.com

adapt to the medical, psychological, and family implications derived from the risk of developing cancer³. As part of the CGC, it is important to inform the participants about preventive measures, the probability of transmitting the mutation and the consequent risk to their descendants, as well as to support them in making informed decisions. In addition, CGC coordinates the communication between several professionals to provide comprehensive care to the participants and their families⁴, including emotional support by a psychologist^{4,5}. Emotional reactions are diverse in CGC participants: stress, fear, worries, anger, frustration, anxiety, guilt, loneliness^{6,7}, and hostility⁸.

In Guadalajara, Mexico, the CGC service (CGCS) exists since 2012. This CGCS is led by the *Universidad de Guadalajara*, in collaboration with the *Instituto Jalisciense de Cancerología*, the *Hospital Civil de Guadalajara*, and City of Hope, Medical Cancer Center from the United States. The Psychological Care Program (PCP) and CGCS have been designed for attend the genetic and psychosocial needs detected in the participants of the involved hospitals. Approval has been obtained to carry out genetic studies and research by this institution.

The aim of this paper is to describe the developmental process and characteristics of the PCP, which is part of the CGCS in Guadalajara, Mexico, for participants with high risk of BC and OC.

Theoretical framework

The psychological management performed during the CGCS is framed within health psychology. It focuses on the emotional care of patients with high risk for hereditary cancer and their families. The health psychology includes promotion of healthy behaviors, family communication, and decision-making strategies⁹.

Cognitive behavioral therapy was selected for patient management because there is a vast evidence of its effectiveness in BC patients¹⁰ and indicates a clear relationship between thoughts, emotions, and behaviors¹¹. Some of the conditions that may be addressed under this approach are anxiety, depression¹², dysfunctional thinking, stigmatization¹³, and stress¹⁴.

Strategies of third wave of behavioral and cognitive therapies are also used, particularly acceptance and commitment therapy and mindfulness. The acceptance and commitment therapy is considered rigorously behavioral¹⁵ and has been implemented within the context of genetic counseling¹⁶.

Finally, the transtheoretical model is one of the most frequently used for behavior change and argues that

individuals go through stages of change which are made up of different processes that occur within each stage. Intervention strategies are suggested according to each stage of change¹⁷.

Development of PCP in the CGC

The PCP was implemented considering several process stages (Fig. 1).

The first step began with a collaboration between the *Centro Universitario de Ciencias de la Salud* of the *Universidad de Guadalajara* and several institutions which included the *Hospital Civil de Guadalajara*, *Instituto Jalisciense de Cancerología*, *Hospital de Especialidades*, and the *Hospital de Ginecoobstetricia del Centro Médico Nacional de Occidente*. This collaboration began in 2006 thanks to the "ELLA Binational BC Study"¹⁸. In 2012, the collaboration with City of Hope Medical Center allowed for professional training in the CGC and for the implementation of the CGCS¹⁹ which is the first service of CGC in Western Mexico⁹. The vision is not only to provide integral, high-quality preventive and medical services but also to provide psychological support. The CGCS team is composed of a geneticist, oncologists, plastic surgeons, nurses, nutritionists, and psychologists (Fig. 2).

A second step included multiple trainings. Oncologists, geneticists, psychologists, and nutritionists provided the trainings in CGC, regarding all aspects of hereditary and familial cancer. This included the molecular basis, clinical phenotypes, and models for genetic risk, prophylactics, as well as nutritional and psychological implications. Moreover, trainings in psycho-oncology were provided with the support of the Susan G. Komen Foundation through the patient navigation program. In addition, the psychologists visited other genetic counseling services in Madrid and Barcelona, Spain, to receive training in psychological management of CGC patients.

As a third step, to establish goals and support the decision-making process for an ideal PCP, an exhaustive and systematic literature review was carried out. On the one hand, several articles and manuals related to the management of CGC patients were consulted, and on the other, scales and intervention strategies were analyzed and selected^{20,21}. This review led to the definition of the PCP goals and guided the decision-making process regarding the pilot test and future implementations.

The pilot test was the fourth step of the development process. Patients were assessed face to face with an




Figure 1. Development of psychological care program within the cancer genetic counseling.

initial version of a semi-structured interview created by the program psychologist and psychosocial scales taken from other CGCSs such as the Hospital Anxiety and Depression Scale (HADS)^{12,22,23} and the Impact of Event Scale^{12,23}.

Based on the pilot test, the fifth step consisted in the definition of scales according to their reliability and utility in CGCS patients. Furthermore, a new scale was created and validated to detect health-risk behaviors²⁴ and the semi-structured interview was improved to detect psychosocial issues in Mexican population²⁵. Intervention and follow-up strategies were implemented and are described below. Due to the high demand for the CGCS, a cooperation with both the patient navigation program²⁶ and psycho-oncology services of hospitals was necessary, to assist as many participants as possible. They provided psychological treatment or referred to another service if they considered it appropriate.

Finally, to increase the number of patients, the sixth step consisted in searching for financial support. In 2016, the CGCS was supported by *Cruzada Avon*. Besides, the program is in the process of consolidation. This involves increasing the professionals trained in CGC, improving the infrastructure, increasing the areas to treat patients and their relatives, and promoting of the program.

Goals of the PCP

In CGCS, the psychologist has a key role in the whole process by detecting and treating psychological variables that may interfere in fulfilling medical recommendations related to prevention and health. Figure 3 shows the psychological attention provided in the CGCS.

The general goals of the PCP are: (1) to assess the psychological state, (2) to offer emotional and decision-making support, and (3) to improve health behavior of CGC participants.

Goal 1: to assess the psychological state

To accomplish the first goal, validated scales such as the HADS²⁷ and the Multidimensional Impact of Cancer Risk Assessment²⁸ are used. The HADS evaluates cognitive and affective aspects of anxiety and depression and assess three dimensions, according to the level of severity: normal, limit and morbidity. In addition, as an essential part of the assessment, an instrument was validated to evaluate health behaviors in people with high risk of cancer based on the transtheoretical model²⁴. Finally, a semi-structured interview regarding issues such as family, social support, psychological




Figure 2. Cancer genetic counseling professionals' interaction.

background, lifestyle, and cancer perception was created²⁵.

The assessment is applied in a private room of the *Instituto Jalisciense de Cancerología* or the *Universidad de Guadalajara* in three distinctive moments: (1) prior to the genetic testing, during the genetic consultation, to determine the appropriateness of the testing, (2) after the delivery of results of the genetic test (ranged from 1 week to 1 month), to assess the psychological consequences of the results, and, (3) during

follow-up, to evaluate any residual psychological issues and their satisfaction with their own health decision-making. The follow-up with patients who received genetic results is carried out face to face or by telephone.

If issues not related to genetic counseling are detected, they are referred to the psycho-oncology service of the *Instituto Jalisciense de Cancerología* (in patients from these hospital) or to the patient navigation program (previously described), which offer psychotherapeutic follow-up.




Figure 3. Psychological management within cancer genetic counseling.

Goals 2 and 3: to offer emotional and decision-making support and to improve health behavior of CGC participants

To achieve the second goal, intervention differs for participants with and without genetic mutation since each group has different specific objectives (Fig. 3) which were identified according to the participants psychosocial assessment and general recommendations of National Comprehensive Cancer Network²⁹.

Decision making aids related to communication of test results or prophylactic surgery have been widely

reported for carriers^{30,31} as well as psycho-education³², reduction of emotional impact³³ and promotion of healthy lifestyles³⁴. For participants with non-informative genetic results, psychoeducational interventions regarding cancer and its risk have been reported³⁵ as well as health behaviors promotion¹².

Techniques implemented

For intervention, techniques are based on cognitive behavioral theory^{14,36,37}, third wave of behavioral and cognitive therapies^{16,38}, and the transtheoretical

Table 1. Techniques used within the psychology service

	Specific objectives	Techniques	Theoretical framework
Participants with genetic mutation	– To decrease psychological affections	– Acceptance and normalization of emotions related to the genetic results. – Relaxation techniques – Mindfulness techniques	– Acceptance and commitment theory – Cognitive behavioral theory – Mindfulness
	– To clarify erroneous patient information	– Interview and psychoeducation	
	– To help in decision-making (prophylactic and preventives alternatives, communication of result with family)	– Decisional balance according to personal values	– Acceptance and commitment theory
	– To promote healthy behaviors.	– Techniques for modifying health risk behaviors (i.e., contingencies management, psychoeducation, reinforcement, activity planning, and social support)	– Transtheoretical model
Participants without mutation	– To clarify erroneous patient information.	– Interview and psychoeducation	
	– To promote healthy behaviors.	– Techniques for modifying health risk behaviors	– Transtheoretical model
	– To implement psychoeducation about cancer and its risk factors.	– Psychoeducation	

model³⁹ (Table 1). The number of sessions and the techniques implemented in each patient varies according to the needs presented. The duration of each session is approximately of 1 h.

Characteristics of the participants

More than 500 participants were treated in the CGCS from 2012 to 2019. The sociodemographic characteristics of the participants evaluated in the PCP are shown in Table 2. The PCP attended 195 participants because they agreed to attend. All the participants took the genetic test. The follow-up was carried in 25% (n = 49) of all the participants. It is worth to mention that this follow-up was focused on patients whose results were positive for genetic mutation, achieving up to 75% corresponding to 18 of 24 positive cases. The sessions with that patients range from 4 to 7. Some patients with genetic mutation did not receive follow-up due to decline to participate, were uncontactable or they died.

To some patients with non-informative results, a session for psychological assessment was provided. The main criteria for the follow-up of the non-informative patients were accept to participate.

Based on initial evaluation, the anxiety symptoms were found in 33% of the participants and depression

Table 2. Sociodemographic characteristics of participants

Age	M ± SD
	45.7 ± 10.28
Marital status	n (%)
Married/having a steady partner	125 (64.2)
Divorced/widowed	28 (15)
Single	40 (21)
Education level	
Illiterate	2 (1)
Middle*	121 (62)
High*	69 (35)
Employment status	
Employed	78 (40)
Not employed	114 (58)
Mutation status	
Positive	24 (12)
Negative	109 (56)
Not known	62 (32)

*Middle: elementary school, middle school, high school; High: college and postgraduate degree.

in 19% (Table 3). Recently, results were published and showed that recurrent anxiety and depression are correlated with recurrent worries, grief, and sleep problems²⁵. Regarding health behaviors, we found that the

Table 3. Results of the scales used

		Normal, n (%)	Borderline ,n (%)	Morbidity ,n (%)
HADS*	Anxiety	107 (66.4)	21 (13)	33 (20.4)
	Depression	129 (80)	18 (11.1)	14 (8.6)
MICRA*		Distress	Uncertainty	Positive experiences
		m (SD)	m (SD)	m (SD)
		7.6 (8.3)	11 (10.8)	5 (6.4)
HBSCQ*		With risk behavior	Without risk behavior	
		n (%)	n (%)	
	Tobacco smoking	9 (7)	115 (93)	
	Alcohol drinking	6 (5)	118 (95)	
	Physical activity	58 (48)	64 (52)	
	Use of mammography and/or ultrasound	7 (6)	112 (94)	

*HADS: Hospital Anxiety and Depression Scale; MICRA: Multidimensional Impact of Cancer Risk Assessment; HBSCQ: Health Behavior and Stages of Change Questionnaire.

insufficient physical activity was the main risk behavior in the participants (Table 3).

Finally, other recently reported results show that uncertainty is very common in positive mutation carriers as well as anxiety. The main findings included that the personal values and the emotional impact of carriers are related to their decision-making. This decision-making was mainly focused on prophylactic surgeries. Some of the perceived benefits of this procedure were the risk reduction and calmness⁴⁰.

Discussion

Psychosocial management in CGC has been extensively studied^{9,12,20,40-42}. However, emotional support is often not provided by experts in psycho-oncology. Instead, other health professionals such as the genetic counselor or geneticist provided it. They evaluate, detect, and try to inform about psychosocial aspects associated with CGC, and they referral to psychology or psychiatry services in cases they deem necessary^{20,42-47}. Nevertheless, many psychologists or psychiatrists do not know the clinical and emotional implications of CGC of the patients derived.

Other authors report psychosocial interventions with CGC population, but they did not clarify whether such interventions were part of the standard care of CGCSs or they were an independent service^{14,16,30}. In relation to these kinds of psychosocial managements, Bensend

(2013) found negative long-term consequences in participants of CGC who had received the service by non-experts in this area. It is important that CGCSs and all professionals involved, including psychologists, are adequately trained to attend participants of CGC.

Finally, there are few works (mainly clinical guidelines) by Ibero-American countries^{42,48,49}, which evidence and describe the work of the psychologist within CGCSs. The PCP tries to encourage the inclusion of the psycho-oncologist into the multidisciplinary work of CGCSs. These professionals must have medical knowledge about hereditary syndromes. Furthermore, they must interact daily and actively with all members of the service^{48,49}. Psychological support can help participants to understand the significance of their genetic risk not only in the social and psychological realm but also in family dynamics⁵⁰. Moreover, the care of psychological issues is critical in CGC, resulting in an optimal quality of life for individuals and their families²¹.

Final considerations and next steps

Some of the strengths that support the PCP are as follows: (1) the cooperation between hospitals and the university; (2) the multidisciplinary interaction during the CGC process; (3) the creation of instruments, such as semi-structured interviews and the health-related behaviors questionnaire, which are tailored to the participants and to the health-care system specific needs;

and (4) the training to CGC psychologists in the hereditary cancer and the clinical management of individuals with high risk for cancer. In addition, other implications are the cooperation of complementary services, the healthy lifestyles promotion among participants with and without genetic mutation, and follow-up (face to face and telephone) for monitoring the psychological state of patients.

Next steps for improve the PCP are: to increase professionals with training in CGC, improve the CGC infrastructure, promote the PCP to increase the number of patients, obtain more national and international grants, extend psychological attention to family members, standardize and certify the program, and evaluate the impact of the program.

Acknowledgment

The authors would like to thank Dr. Jeffrey Weitzel from the City of Hope National Medical Center for his support within the Clinical Cancer Genetics Community Research Network. Besides to Susan G. Komen for the Cure by its support in psycho-oncological training through the patient navigation program. Thanks to hospitals that contributed to the CGCS, especially to psycho-oncology service of the *Instituto Jalisciense de Cancerología*. Thanks to the patient navigation program for its help in the psychological support of the CGC patients. To Erendira Camacho, Tania Morales, and Ricardo García for their support during the evaluations and follow-up of CGC participants. Finally, the authors wish to thank Nestor I. Martínez Torres and Dr. Paul Callahan for their support in the editing of the English language version of this article.

Conflicts of interest

The authors declare no conflicts of interest.

Funding

This work was supported by Avon-Mexico (Cruzada contra el Cáncer de mama 2015 and Avon, Mexico, Promesa Avon contra el cáncer de mama-2018) to Adrián Daneri-Navarro, University of Guadalajara, CGCS.

Ethical disclosures

Protection of people and animals. The authors declare that no human or animal experiments have been performed for this research.

Confidentiality of the data. The authors declare that they have followed the protocols of their workplace regarding the publication of patient data.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

References

1. Judkins T, Leclair B, Bowles K, Gutin N, Trost J, McCulloch J, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. *BMC Cancer*. 2015;15:215.
2. Saam J, Moyes K, Landon M, Williams K, Kaldane RR, Arnell C, et al. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis. *Oncology*. 2015;38:226-33.
3. Balobaid A, Qari A, Al-Zaidan H. Genetic counselors' scope of practice and challenges in genetic counseling services in Saudi Arabia. *Int J Pediatr Adolesc Med*. 2016;3:1-6.
4. Lastra-Aras E, Robles-Díaz L, Guillén-Ponce C, Alba E, Cruz JJ. SEOM recommendations on the structure and operation of hereditary cancer genetic counseling units (HGCCUs). *Clin Transl Oncol*. 2013;15:20-5.
5. Ertmanski S, Metcalfe K, Trempala J, Glowacka M, Lubrinski J, Narod S, et al. Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation. *Hered Cancer Clin Pract*. 2012;10:A14.
6. Reeve J, Owens RG, Winship IM. Psychological impact of predictive testing for colonic cancer. *J Health Psychol*. 2000;5:99-108.
7. Eijzenga W, Hahn DE, Aaronson NK, Kluijft I, Bleeker EM. Specific psychosocial issues of individuals undergoing genetic counseling for cancer-a literature review. *J Genet Couns*. 2014;23:133-46.
8. Annunziata MA, Muzzatti B, Narciso D, Mellà S, Viel A, Bidoli E, et al. Mood state profile and coping strategies after BRCA-1/2 genetic test disclosure: a retrospective study in Italy. *Support Care Cancer*. 2011; 19:733-5.
9. Ramírez LP, De la Roca Chiapas JM, Navarro AD, Colunga-Rodríguez C, Contreras AM, Martínez-Arriaga R, et al. Consejo genético oncológico: las aplicaciones de la Psicooncología. *Gac Mex Oncol*. 2016;15:145-9.
10. D'Egidio V, Sestili C, Mancino M, Sciarra I, Cocchiara R, Backhaus I, et al. Counseling interventions delivered in women with breast cancer to improve health-related quality of life: a systematic review. *Qual Life Res*. 2017;26:2573-92.
11. Ruiz MA, Díaz MI, Villalobos A. Manual de Técnicas de Intervención Cognitivo Conductuales. Spain: Descleé De Brouwer, S.A.; 2012.
12. Hirschberg AM, Chan-Smutko G, Pirl WF. Psychiatric implications of cancer genetic testing. *Cancer*. 2015;121:341-60.
13. Vos J, van Asperen CJ, Oosterwijk JC, Menko FH, Collee MJ, Garcia EG, et al. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters. *Psychooncology*. 2013;22:902-10.
14. Landau C, Lev-Ari S, Cohen-Mansfield J, Tillinger E, Geva R, Tarrasch R, et al. Randomized controlled trial of inquiry-based stress reduction (IBSR) technique for BRCA1/2 mutation carriers. *Psychooncology*. 2015;24:726-31.
15. Hayes SC. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. *Behav Ther*. 2004;35:639-665.
16. Broley S. Acceptance and commitment therapy in genetic counselling: a case study of recurrent worry. *J Genet Couns*. 2013;22:296-302.
17. Prochaska JO, Redding CA, Evers KE. Transtheoretical model and stages of change. In: Glanz K, Rimer BK, Viswanath K, editors. *Health Behavior and Health Education: theory, Research and Practice*. 4th ed. San Francisco: John Wiley & Sons, Inc.; 2008. p. 97-121.
18. Martínez ME, Gutiérrez-Millán LE, Bondy M, Daneri-Navarro A, Maza-Montenegro MM, Anduro-Corona I, et al. Comparative study of breast cancer in Mexican and Mexican-American women. *Health*. 2010;2:1040-8.
19. Weitzel JN, Villarreal-Garza C, Blazer KR, Herzog J, Castillo D, Chávez T, et al. Abstract 3465: dissemination and implementation of genomic cancer risk assessment in Latin America via innovative pairing of clinical training and genomic tools. *Cancer Res*. 2016;76:3465.
20. Christinat A, Pagani O. Practical aspects of genetic counseling in breast cancer: lights and shadows. *Breast*. 2013;22:375-82.
21. Cruzado JA, Segura PP, Olivera H. Consecuencias y necesidades de la intervención psicológica en consejo genético para mujeres en riesgo de cáncer de mama hereditario. *Psicooncología*. 2007;4:465-82.

22. Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. *Fam Cancer*. 2006;5:61-75.
23. Geirdal AO, Reichelt JG, Dahl AA, Heimdal K, Maehle L, Stormorken A, et al. Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations. *Fam Cancer*. 2005;4:121-6.
24. Gonzalez-Ramirez LP, De la Roca-Chiapas JM, Colunga-Rodriguez C, Preciado-Serrano ML, Daneri-Navarro A, Pedroza-Cabrera FJ, et al. Validation of health behavior and stages of change questionnaire. *Breast Cancer (Dove Med Press)*. 2017;9:199-205.
25. Gonzalez-Ramirez LP, Martinez-Arriaga R, Camacho-Cardenas E, Del Toro-Valero A, Oceguera-Villanueva A, Zagamé L, et al. Evaluation of psychosocial aspects in participants of cancer genetic counseling. *Hered Cancer Clin Pract*. 2017;15:13.
26. Solis AG. Innovador Tratamiento Psicológico Para Pacientes con Cáncer. Quito: Agencia Informativa Conacyt; 2015.
27. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatri Scand*. 1983;67:361-70.
28. Cella D, Hughes C, Peterman A, Chang C, Peshkin BN, Schwartz MD, et al. A brief assessment of concerns associated with genetic testing for cancer: the multidimensional impact of cancer risk assessment (MICRA) questionnaire. *Health Psychol*. 2002;21:564-72.
29. Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, Version 2. 2017. *J Natl Compr Canc Netw*. 2017;15:9-20.
30. Chiavari L, Gandini S, Ferro I, Guerrieri-Gonzaga A, Russell-Edu W, Bonanni B, et al. Difficult choices for young patients with cancer: the supportive role of decisional counseling. *Support Care Cancer*. 2015;23:3555-62.
31. Culver JO, MacDonald DJ, Thornton AA, Sand SR, Grant M, Bowen DJ, et al. Development and evaluation of a decision aid for BRCA carriers with breast cancer. *J Genet Couns*. 2011;20:294-307.
32. Graves KD, Wenzel L, Schwartz MD, Luta G, Wileyto P, Narod S, et al. Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev*. 2010;19:648-54.
33. Eijzenga W, Bleeker EM, Hahn DE, Van der Kolk LE, Sidharta GN, Aaronsen NK. Prevalence and detection of psychosocial problems in cancer genetic counseling. *Fam Cancer*. 2015;14:629-36.
34. Baars JE, van Dulmen AM, Velthuizen ME, van Riel E, Ausems MG. Breast cancer genetic counseling among Dutch patients from Turkish and Moroccan descent: participation determinants and perspectives of patients and healthcare professionals. *J Community Genet*. 2017;8:97-108.
35. Henneman L, Oosterwijk JC, van Asperen CJ, Menko FH, Ockhuyzen-Vermeij CF, Kostense PJ, et al. The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial. *BMC Med Inform Decis Mak*. 2013;13:55.
36. McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, et al. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention. *Am J Med Genet A*. 2004;130:221-7.
37. Miller SM, Fleisher L, Roussi P, Buzaglo JS, Schnoll R, Slater E, et al. Facilitating informed decision making about breast cancer risk and genetic counseling among women calling the NCI's cancer information service. *J Health Commun*. 2005;10:119-36.
38. Boyle CC, Stanton AL, Ganz PA, Crespi CM, Bower JE. Improvements in emotion regulation following mindfulness meditation: effects on depressive symptoms and perceived stress in younger breast cancer survivors. *J Consult Clin Psychol*. 2017;85:397-402.
39. Menezes MC, Mingoti SA, Cardoso CS, Mendonça Rde D, Lopes AC. Intervention based on transtheoretical model promotes anthropometric and nutritional improvements-a randomized controlled trial. *Eat Behav*. 2015;17:37-44.
40. Arriaga RM, García RR, de Santos Avila F, Lerma-Talamantes A, González-Ramírez LP, Toro-Valero A, et al. Toma de decisiones, valores personales e impacto emocional en pacientes con cáncer de mama con mutación genética en BRCA12. *Uaricha*. 2018;15:55-66.
41. DeMarco TA, Smith KL, Nusbaum RH, Peshkin BN, Schwartz MD, Isaacs C. Practical aspects of delivering hereditary cancer risk counseling. *Semin Oncol*. 2007;34: 369-78.
42. Palmero EI, Kalakun L, Schüller-Faccini L, Giugliani R, Vargas FR, Rocha JC, et al. Cancer genetic counseling in public health care hospitals: the experience of three Brazilian services. *Community Genet*. 2007;10:110-9.
43. Miller FA, Giacomini M, Ahern C. Contending visions in the evolution of genetic medicine: the case of cancer genetic services in Ontario, Canada. *Soc Sci Med*. 2008;67:152-60.
44. Than NG, Papp Z. Ethical issues in genetic counseling. *Best Pract Res Clin Obstet Gynaecol*. 2017;43:32-49.
45. Valdespino-Gómez V, Valdespino-Castillo V. Utilidad de la consulta oncogenética molecular en individuos adultos con cáncer familiar. *Rev Med Inst Mex Seguro Soc*. 2016;54:364-74.
46. Oberguggenberger A, Sztankay M, Morscher RJ, Sperner-Unterweger B, Weber I, Hubalek M, et al. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: a patient-reported outcome study. *J Psychosom Res*. 2016;89:39-45.
47. Buchanan AH, Datta SK, Skinner CS, Hollowell GP, Beresford HF, Freeland T, et al. Randomized trial of telegenetics vs. In-person cancer genetic counseling: cost, patient satisfaction and attendance. *J Genet Couns*. 2015;24:961-70.
48. Núñez LM, Cólica V, Valdez R, Telias D, Schenone G. *Asesoramiento Genético en Oncología: manual Para la Práctica Clínica*. Buenos Aires: Instituto Nacional del Cáncer. 2013.
49. Segura PP. Modelos y organización de una unidad de consejo genético. *Psicooncología*. 2005;2:261-8.
50. Lewis KM. Identifying hereditary cancer: genetic counseling and cancer risk assessment. *Curr Probl Cancer*. 2014;38:216-25.